No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Design Therapeutics, Inc. (DSGN) stock was $12.11 as of Oct 6, 2026, 10:05 AM EDT, down 2.47% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +102.6% · 3-year avg +73.9%/yr · 5-year avg -3.8%/yr
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions.
Biotechnology · Carlsbad, CA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.38
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.32
vs Estimate
$-0.34
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DSGN | $756.55M | $12.11 | -2.47% | +102.59% | -3.82% | N/A | N/A |
| 2CADL | $752.12M | $10.27 | +0.34% | +83.46% | -1.42% | N/A | vs DSGN |
| 3CTKB | $772.27M | $5.98 | -1.81% | +53.09% | -23.16% | N/A | vs DSGN |
| 4LXRX | $772.90M | $1.74 | N/A | +23.28% | -18.54% | -21.03% | vs DSGN |
| 5GERN | $773.03M | $1.21 | -0.41% | -10.32% | -1.87% | -6.18% | vs DSGN |
| 6ATTO | $777.55M | $18.07 | +0.42% | N/A | N/A | N/A | vs DSGN |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$21.71
+79.3% upside
Low
$20.00
Current
$12.11
High
$26.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.35 | $-0.34 | $-0.32 | 5 |
| Quarter ending Dec 2026 | $-0.46 | $-0.38 | $-0.29 | 5 |
| Quarter ending Mar 2027 | $-0.36 | $-0.36 | $-0.36 | 3 |
| Quarter ending Jun 2027 | $-0.38 | $-0.38 | $-0.38 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.52 | $-1.32 | $-1.15 | 6 |
| FY 2027 | $-1.99 | $-1.59 | $-1.14 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $117.33M | $117.33M | $117.33M | 8 |
| FY 2027 | $204.78M | $204.78M | $204.78M | 8 |
